ideasIdea
Circulating tumour cell clearance as the phase 2 gate for anti-metastatic drugs
Cancer cells travelling in the blood can be counted. If a drug clears them, that is an early sign it may stop spread, and it reads out in weeks rather than years.
CTC count is an established prognostic marker in metastatic breast, prostate and colorectal cancer, and CTC conversion from unfavourable to favourable has been used as a response measure in prostate cancer. Anti-metastatic mechanisms such as platelet cloaking, trap-mediated capture and cluster formation should show up as CTC and CTC-cluster clearance long before imaging changes. A standardised cluster readout would give small, cheap, fast phase 2 decisions.
Hypothesis
Failure to reduce CTC cluster burden by half at four weeks predicts absence of metastasis-free survival benefit with high negative predictive value, allowing most anti-metastatic candidates to be killed in trials of under 60 patients.
Rationale
Clusters rather than single cells carry most metastatic potential in mouse and human studies, and their abundance is dynamic and drug-responsive. Clearance-based go/no-go decisions already work in leukaemia through MRD and in prostate cancer through PSA and CTC conversion.
What would test it
Add a harmonised CTC and cluster assay to three ongoing perioperative or adjuvant trials, and test the association between four-week clearance and relapse; publish the assay and thresholds openly.
Maturity
early clinical
Who has to act
industry
Cost to try
Medium ($1M to $50M)
Years to first evidence
4
Bottlenecks it attacks
- Metastasis is understood least and studied last · Metastasis causes about nine in ten cancer deaths but gets a small fraction of research money and almost no trials of its own.
- Biomarkers are not validated or standardised · Tests that decide who gets a drug are often not validated prospectively and are measured differently in every lab.